Zenosense Inc. ZENO Archives - Page 2 of 4

FridayJul 27, 2018 11:45 am

QualityStocksNewsBreaks – Zenosense, Inc.’s (ZENO) MIDS Cardiac™ Device Proves Potential to Saves Lives through Early Detection

Zenosense (OTC: ZENO) recently reported the successful completion of a second round of testing for its MIDS Cardiac™ device, a patented handheld point-of-care (“POC”) technology for the detection of heart attack. An article discussing the device reads: “According to the World Health Organization, early detection is one of the most important prerequisites for the successful management of cardiovascular problems. … With detection equal or superior to state of the art laboratory analyzers and advanced portability allowing it to be used at point of care, including in an emergency setting, MIDS Cardiac™ would be an absolute game changer which could help…

TuesdayJul 24, 2018 1:05 pm

Zenosense, Inc. (ZENO) Posts Test Results, Now Trading on OTCQB Venture Market

Second round of testing for MIDS Cardiac™ detection technology for cardiac emergency triage reveals breakthrough quantitative testing results American Heart Association projects that 130 million adults in the U.S. will have some form of cardiovascular disease by 2035, with total costs expected to reach $1.1 trillion Studies performed outside the United States have demonstrated that high-sensitivity troponin testing speeds the triage of patients with suspected acute myocardial infarction (AMI, “Heart Attack”) Identifying low levels of troponin using a rapid-response, handheld diagnostic device for cardiac emergency triage can speed the treatment of AMI and improve treatment outcomes Identifying a low-risk patient could permit…

WednesdayJul 18, 2018 11:33 am

QualityStocksNewsBreaks – Zenosense, Inc.’s (ZENO) MIDS Cardiac Device Demonstrates Testing Potential

Through a joint-venture ownership in MIDS Medical Ltd., Zenosense (OTC: ZENO) is developing MIDS Cardiac™, a rapid cardiac diagnostic device. An article discussing the device reads: “In the new testing, the joint venture aimed to magnetically detect assay beads below the 200,000 level in order to support a finding that the technology could be effective in a high-sensitivity troponin test. Previously, the technology had detected down to around 100,000 beads; the new testing brings this down to around the 50,000-bead level, indicating that it is well within the necessary level of detection required for a high-sensitivity assay (http://ibn.fm/mtBiA). The new testing used…

ThursdayJul 12, 2018 1:09 pm

Zenosense, Inc. (ZENO) Reports Successful Quantitative Testing Results for MIDS Cardiac™ Technology

Cardiovascular diseases are costing the U.S. $1 billion per day in medical fees and productivity losses The number of heart attacks is increasing on an annual basis, highlighting the importance of early detection technology Zenosense is developing a handheld device that could significantly lower cardiovascular-related death rate and associated medical costs by enabling swift, accurate diagnostic Health care technology company Zenosense, Inc. (OTC: ZENO) has announced the successful completion of a second round of testing for its MIDS Cardiac™ detection technology – a handheld system designed to rapidly test for certain cardiac biomarkers at the point of care, saving medical…

TuesdayJul 10, 2018 11:04 am

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Begins Trading on the OTCQB Venture Market

Healthcare technology company Zenosense (OTC: ZENO) this morning announced that the company has started trading on the OTC Markets Group OTCQB “Venture Market”. Known as an established public market by the U.S. Securities and Exchange Commission (“SEC”), the OTCQB is a leading market for entrepreneurial and development stage companies operating in the U.S. and internationally. Companies must provide up-to-date financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process to meet the eligibility requirements to list on the market. By trading on the OTCQB Venture Market, Zenosense is better positioned to build…

TuesdayJul 03, 2018 10:02 am

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Poised to Capitalize on Fast-growing Market

Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing “MIDS”, a nano-magnetic detection technology to allow true laboratory accuracy at the point-of-care (“POC”). A recent article discussing the company reads: “Zenosense, through MML, intends to develop wider applications of its MIDS technology platform to include POC immunoassay testing of many other medical conditions and diseases. MML’s test results on its Hybrid Strip development system already indicate that MML can detect commercially available assay beads at extremely low levels. The successful incorporation of magnetic detection should provide a significant improvement in accuracy…

MondayJul 02, 2018 12:47 pm

Zenosense, Inc. (ZENO) – Cardiac Triage Technology Proves Capability

Joint Venture MIDS technology doubles detection capability in second testing round MIDS Technology aims to provide ambulance personnel, ERs with a fast, easy, low-cost and powerful device to diagnose potential cardiac symptoms Chest pain diagnosis is one of the most common challenges for outpatient medical providers to assess When first responders provide treatment to patients complaining of chest pain, they face the critical task of determining what medical intervention is necessary with as much immediacy as possible. Although such diagnoses can be difficult, particularly away from a clinical laboratory setting, Zenosense Inc. (OTC: ZENO), through a joint-venture ownership in MIDS…

FridayJun 29, 2018 11:37 am

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Developing Technology to Deliver High-sensitivity Laboratory Accuracy in Emergency Settings

Healthcare technology company Zenosense (OTC: ZENO) is currently developing its MIDS Cardiac handheld diagnostic technology to provide rapid cardiac biomarker tests in emergency settings. A recent article discussing the company reads: “MIDS goes beyond the optical technology used by most immunoassay tests. The analytical sensitivity gap between central laboratory testing platforms and existing POC testing devices is significant as this bulky optical technology has not been successfully miniaturized into high sensitivity capable, handheld devices. In contrast, the MIDS technology uses highly sensitive, custom-built “Hall Effect” magnetic sensors that allow it to detect extremely low levels of magnetic field disturbance caused…

WednesdayJun 27, 2018 12:05 pm

Zenosense, Inc. (ZENO) Well Positioned to Capitalize on Accelerated Market Penetration of Point-of-Care Diagnostics Devices

POC devices speed up triage, diagnosis and treatment of patients MIDS Cardiac™ is being developed to detect the biomarker troponin I or T for suspected heart attack within 3 minutes, as opposed to often taking 60 minutes in central laboratories Global cardiac biomarkers market expected to reach $13.3 billion by 2024 A recent report by Grand View Research analyzes the shortage of skilled medical staff and how this is expected to accelerate the market penetration rate of point-of-care (POC) diagnostic products (http://ibn.fm/6Yb2x). The major advantage of these devices is that they can be operated by both qualified medical professionals and…

WednesdayMay 02, 2018 2:32 pm

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Aims to Provide First Responders with Handheld Diagnostic Device for Cardiac Emergency

Healthcare technology company Zenosense (OTC: ZENO), through its joint venture ownership of MIDS Medical Limited (“MML”), is developing MIDS Cardiac™ to give first responders a rapid, highly sensitive analysis of heart biomarkers. An article discussing the company reads: “This handheld device aims to deliver accuracy equal or superior to these ‘gold standard’ central laboratory analyzers at the POC – taking lab testing to the patient. MIDS Cardiac aims to deliver high sensitivity results that are available within minutes. This would provide first responders with a new level of point of care device analysis. It will save valuable time during the…

Site Search

Company Search

Tag: Zenosense Inc. ZENO